PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions.

Abstract Benznidazole (BNZ) is a drug available for the etiological treatment of Chagas disease. However, this drug is toxic and has a limited effectiveness on the chronic phase of this disease, often leading to poor treatment adherence.
PMID
Related Publications

Adverse systemic reaction to benznidazole.

Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country.

Tolerance of benznidazole in a United States Chagas Disease clinic.

Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará.

Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.

Authors

Mayor MeshTerms
Keywords
Journal Title revista da sociedade brasileira de medicina tropical
Publication Year Start




PMID- 28700051
OWN - NLM
STAT- MEDLINE
DA  - 20170712
DCOM- 20170731
LR  - 20170731
IS  - 1678-9849 (Electronic)
IS  - 0037-8682 (Linking)
VI  - 50
IP  - 3
DP  - 2017 May-Jun
TI  - Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole:
      drug-related problems and pharmaceutical interventions.
PG  - 334-340
LID - S0037-86822017002300334 [pii]
LID - 10.1590/0037-8682-0474-2016 [doi]
AB  - INTRODUCTION: Benznidazole (BNZ) is a drug available for the etiological
      treatment of Chagas disease. However, this drug is toxic and has a limited
      effectiveness on the chronic phase of this disease, often leading to poor
      treatment adherence. METHODS:: This is a descriptive and exploratory study
      conducted at the Pharmaceutical Care Service for Chagas disease patients of the
      Federal University of Ceara. Drug-related problems (DRPs) and pharmaceutical
      interventions (PIs) were classified according to the Second Consensus of Granada.
      RESULTS:: The average age of patients with Chagas disease was 62 years, with the 
      majority residing in the Ceara countryside (86.7%), and having low education
      levels (63.3% with elementary school education). Regarding family income, most
      patients belonged to a household that earned </=1-2 times the minimum wage per
      month. Approximately 73% of these patients complied with the BNZ treatment, and
      nearly 7% underwent therapy interruption after medical evaluation. A total of 189
      DRPs were identified, of which 51.9% (n=98) were classified as potential, and
      48.1% (n=91) as actual. The most frequent DRPs were related to safety
      (qualitative safety; n=70; 37%), necessity (non-adherence; n=52; 27.5%), and
      effectiveness (qualitative effectiveness/non-optimal drug selection; n=45;
      23.8%). Among the 216 PIs conducted, the majority were related to patient
      education (n=168; 77.8%) and pharmacological strategy (n=42; 19.4%).
      CONCLUSIONS:: This study indicates the need for pharmacotherapeutic monitoring in
      patients with Chagas because of the high number of therapeutic interventions,
      DRPs (approximately 3 DRPs/patient), BNZ adherence, and polypharmacy.
FAU - Correia, Joao Paulo Ramalho
AU  - Correia JPR
AD  - Laboratorio de Pesquisa em Doenca de Chagas, Departamento de Analises Clinicas,
      Universidade Federal do Ceara, Fortaleza, CE, Brasil.
FAU - Costa, Alanna Carla da
AU  - Costa ACD
AD  - Laboratorio de Pesquisa em Doenca de Chagas, Departamento de Analises Clinicas,
      Universidade Federal do Ceara, Fortaleza, CE, Brasil.
AD  - Programa de Pos-Graduacao Stricto Sensu em Ciencias Farmaceuticas, Universidade
      Federal do Ceara, Fortaleza, CE, Brasil.
FAU - Rocha, Eduardo Arrais
AU  - Rocha EA
AD  - Hospital Universitario Walter Cantidio, Universidade Federal do Ceara, Fortaleza,
      CE, Brasil.
FAU - Quidute, Ana Rosa Pinto
AU  - Quidute ARP
AD  - Hospital Universitario Walter Cantidio, Universidade Federal do Ceara, Fortaleza,
      CE, Brasil.
FAU - Candido, Darlan da Silva
AU  - Candido DDS
AD  - Programa de Pos-Graduacao Stricto Sensu em Alergia e Imunopatologia, Faculdade de
      Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brasil.
FAU - Ponciano, Angela Maria de Souza
AU  - Ponciano AMS
AD  - Departamento de Farmacia, Centro de Estudos em Atencao Farmaceutica, Universidade
      Federal do Ceara, Fortaleza, CE, Brasil.
FAU - Fonteles, Marta Maria de Franca
AU  - Fonteles MMF
AD  - Programa de Pos-Graduacao Stricto Sensu em Ciencias Farmaceuticas, Universidade
      Federal do Ceara, Fortaleza, CE, Brasil.
AD  - Departamento de Farmacia, Centro de Estudos em Atencao Farmaceutica, Universidade
      Federal do Ceara, Fortaleza, CE, Brasil.
FAU - Oliveira, Maria de Fatima
AU  - Oliveira MF
AD  - Laboratorio de Pesquisa em Doenca de Chagas, Departamento de Analises Clinicas,
      Universidade Federal do Ceara, Fortaleza, CE, Brasil.
AD  - Programa de Pos-Graduacao Stricto Sensu em Ciencias Farmaceuticas, Universidade
      Federal do Ceara, Fortaleza, CE, Brasil.
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Rev Soc Bras Med Trop
JT  - Revista da Sociedade Brasileira de Medicina Tropical
JID - 7507456
RN  - 0 (Nitroimidazoles)
RN  - 0 (Trypanocidal Agents)
RN  - YC42NRJ1ZD (benzonidazole)
SB  - IM
MH  - Brazil
MH  - Chagas Disease/*drug therapy
MH  - Drug-Related Side Effects and Adverse Reactions/*classification
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Medication Adherence/*statistics & numerical data
MH  - Middle Aged
MH  - Nitroimidazoles/adverse effects/*therapeutic use
MH  - Socioeconomic Factors
MH  - Trypanocidal Agents/adverse effects/*therapeutic use
EDAT- 2017/07/13 06:00
MHDA- 2017/08/02 06:00
CRDT- 2017/07/13 06:00
PHST- 2016/11/21 [received]
PHST- 2017/06/02 [accepted]
AID - S0037-86822017002300334 [pii]
AID - 10.1590/0037-8682-0474-2016 [doi]
PST - ppublish
SO  - Rev Soc Bras Med Trop. 2017 May-Jun;50(3):334-340. doi:
      10.1590/0037-8682-0474-2016.